keyword
MENU ▼
Read by QxMD icon Read
search

Indolent lymphoma

keyword
https://www.readbyqxmd.com/read/29340116/t-follicular-helper-cells-a-potential-therapeutic-target-in-follicular-lymphoma
#1
REVIEW
Jordi Ochando, Mounia S Braza
Follicular lymphoma (FL), the most common indolent B-cell non-Hodgkin lymphoma (B-NHL), is a germinal center (GC)-derived lymphoma. The mechanisms underlying B-cell differentiation/maturation in GCs could be also involved in their malignant transformation. Moreover, the non-malignant cell composition and architecture of the tumor microenvironment can influence FL development and outcome. Here, we review recent research advances on CD4 helper T cells in FL that highlight the pivotal role of T follicular helper (TFH) cells in a complex multicellular system where they interact with B cells during GC dynamics...
December 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29339810/extrahepatic-cancers-and-chronic-hcv-infection
#2
REVIEW
Stanislas Pol, Anaïs Vallet-Pichard, Olivier Hermine
Infectious agents, such as HCV, account for ∼15% of human cancers. HCV infects not only hepatocytes but also extrahepatic cells. Chronic HCV infection can induce chronic inflammation with qualitative and quantitative alterations of the immune repertoire and tissue microenvironment, which could induce various neoplasias. Epidemiological studies and meta-analyses suggest an increased rate of extrahepatic cancers in patients with chronic HCV infection along with a higher risk of intrahepatic cholangiocarcinoma, pancreatic cancer and non-Hodgkin lymphoma (NHL), highlighting the need to screen for HCV infection in patients with these cancers...
January 17, 2018: Nature Reviews. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29332711/very-low-dose-versus-standard-dose-radiation-therapy-for-indolent-primary-cutaneous-b-cell-lymphomas-a-retrospective-study
#3
Amrita Goyal, Joi B Carter, Itai Pashtan, Sara Gallotto, Irene Wang, Scott Isom, Andrea Ng, Karen M Winkfield
No abstract text is available yet for this article.
February 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29317554/bendamustine-plus-rituximab-versus-r-chop-as-first-line-treatment-for-patients-with-follicular-lymphoma-grade-3a-evidence-from-a-multicenter-retrospective-study
#4
Patrizia Mondello, Normann Steiner, Wolfgang Willenbacher, Claudio Cerchione, Davide Nappi, Endri Mauro, Simone Ferrero, Salvatore Cuzzocrea, Michael Mian
BACKGROUND: Rituximab plus bendamustine (R-B) has been demonstrated to improve outcomes and reduce toxicity compared with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) in follicular lymphoma (FL). Nevertheless, in clinical practice, many centers still prefer R-CHOP to R-B in patients with FL grade 3A (FL3A). Therefore, we retrospectively assessed patients with FL3A treated with either R-CHOP or R-B in five European cancer centers and compared their outcomes. MATERIALS AND METHODS: We retrospectively assessed 132 patients affected by FL grade 3A treated with either R-B or R-CHOP in the first line and evaluated outcome and toxicity according to the type of treatment...
January 9, 2018: Oncologist
https://www.readbyqxmd.com/read/29314206/follicular-lymphoma-2018-update-on-diagnosis-and-management
#5
Arnold Freedman
DISEASE OVERVIEW: Follicular lymphoma is generally an indolent B cell lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma (FL) is characterized by diffuse lymphadenopathy, bone marrow involvement, splenomegaly and less commonly other extranodal sites of involvement. In general, cytopenias can occur but constitutional symptoms of fever, nightsweats, and weight loss are uncommon. DIAGNOSIS: Diagnosis is based on histology of preferably a biopsy of a lymph node...
February 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29314151/comparison-of-ebv-positive-mucocutaneous-ulcer-ebvmcu-associated-with-treated-lymphoma-or-methotrexate-in-japan
#6
Teerada Daroontum, Kei Kohno, Ahmed E Eladl, Akira Satou, Ayako Sakakibara, Shoichi Matsukage, Naoki Yakushiji, Charin Ya-In, Shigeo Nakamura, Naoko Asano, Seiichi Kato
AIMS: The present study compared treated lymphoma-associated EBV-positive mucocutaneous ulcer (EBVMCU) and methotrexate (MTX)-associated EBVMCU. METHODS AND RESULTS: Of a series of 15 Japanese patients (11 women, 4 men; median age 74 years, range 35-84 years). 7 received MTX for autoimmune disease and 8 developed EBVMCU after treatment of malignant lymphoma (diffuse large B-cell lymphoma [n=4] without EBV association, adult T-cell leukaemia/lymphoma [n=2], angioimmunoblastic T-cell lymphoma [n=1], and follicular lymphoma [n=1])...
January 4, 2018: Histopathology
https://www.readbyqxmd.com/read/29313585/cmv-pneumonitis-following-bendamustine-containing-chemotherapy
#7
Sumeet Vimal Kishor Singhania, Pujan Parikh, Sandeep Goyle
Bendamustine has been increasingly used for treatment of indolent lymphoma for the past few years. The data on safety profile of this drug is still emerging with the increasing use of this drug. The higher occurrence of CMV reactivation with this drug has been reported in few case reports only. We report a case of CMV penumonitis initially presenting as unexplained pyrexia which responded well to intravenous Ganciclovir. This case report re-iterates the suspicion of CMV reactivation in lymphoma patients receiving bendamustine who present with unexplained pyrexia or chest symptoms...
September 2017: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/29301121/association-of-soluble-interleukin-2-receptor-and-c-reactive-protein-with-the-efficacy-of-bendamustine-salvage-treatment-for-indolent-lymphomas-and-mantle-cell-lymphoma
#8
Yukiko Kawaguchi, Tsuyoshi Nakamaki, Maasa Abe, Yuta Baba, So Murai, Megumi Watanuki, Nana Arai, Shun Fujiwara, Nobuyuki Kabasawa, Hiroyuki Tsukamoto, Yui Uto, Hirotsugu Ariizumi, Kouji Yanagisawa, Norimichi Hattori, Hiroshi Harada, Bungo Saito
Bendamustine has demonstrated favourable efficacy in relapsed or refractory indolent lymphoma and mantle cell lymphoma. We retrospectively evaluated the pre-treatment clinical and laboratory factors and their correlation with the clinical outcome of these lymphomas. We analysed 53 patients who had been treated with bendamustine alone (n = 6) or rituximab plus bendamustine (n = 47). The overall response rate was 81.1%, with a complete response (CR) rate of 39.6%. The CR rate was significantly low in patients who had elevated levels of soluble interleukin-2 receptor (p = 0...
January 5, 2018: Acta Haematologica
https://www.readbyqxmd.com/read/29288421/first-line-treatment-with-bendamustine-and-rituximab-in-patients-with-intermediate-high-risk-splenic-marginal-zone-lymphomas
#9
Roberto Castelli, Luigi Bergamaschini, Giorgio Lambertenghi Deliliers
Splenic marginal zone lymphomas (SMZLs) are rare indolent B cell neoplasms that affect the spleen, bone marrow, and blood. Although they have an indolent course in the majority of patients, who have a median survival of 8-10 years, ∼ 30% may experience a worse outcome. The prognostic criteria of progression are lymph node and extra-nodal involvement, high lymphocyte counts, anaemia, and thrombocytopenia. The treatment of SMZLs include a "wait and watch strategy", splenectomy, and alkylating agents ± rituximab...
December 29, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29282393/cd30-cutaneous-anaplastic-large-cell-lymphoma-of-the-upper-eyelid-a-case-report
#10
Stéphanie Olivier, Claire Dachelet, Ivan Theate, Isabelle Tromme, Marie Baeck
CD30+ cutaneous anaplastic large-cell lymphoma is part of the CD30+ T-cell lymphoproliferative disorders. This type of lymphoma is in most cases indolent, with a high survival rate. We report the case of a 59-year-old patient with a 1-month lasting crusty lesion of the upper eyelid. Eyelid involvement is very uncommon, as the most frequent locations are the trunk and the limbs.
September 2017: Case Reports in Dermatology
https://www.readbyqxmd.com/read/29260925/effective-management-strategies-for-patients-with-marginal-zone-lymphoma
#11
Cecilia B Rosand, Kelly Valla, Christopher R Flowers, Jean L Koff
Marginal zone lymphoma (MZL) is an uncommon indolent lymphoma classified into subtypes based on primary site of involvement: splenic, nodal and extranodal. MZLs' relative rarity has largely precluded adoption of a standard management strategy. Here, we provide an overview of the epidemiology, clinical behavior and therapeutic approaches for each subtype. Biologic insights into lymphomagenesis have identified B-cell receptor signaling as a rational therapeutic target. Recent clinical data suggest that novel agents targeting this pathway, including the Bruton's tyrosine kinase inhibitor, ibrutinib, show significant promise in treatment of relapsed MZL...
December 20, 2017: Future Oncology
https://www.readbyqxmd.com/read/29251058/abundant-expression-of-bmi1-in-follicular-lymphoma-is-associated-with-reduced-overall-survival
#12
Naif AlJohani, Suk-Jin Choi, Andrew G Day, Abdulmohsen Alhejaily, Shakeel Virk, Tara Baetz, David P LeBrun
Although generally indolent, follicular lymphoma (FL) sometimes pursues a more aggressive course leading to early death. B-cell-specific Mo-MLV insertion site-1 (BMI1) is a member of the polycomb group (PcG) proteins that confer stem cell properties through gene silencing. We used multi-channel immunofluorescence and automated image analysis to quantify BMI1 selectively in the nuclei of FL-derived B-cells in routine biopsy specimens. Applying this assay to 109 pretreatment FL biopsy samples demonstrates a significant association between abundant BMI1 and reduced overall survival (p = ...
December 18, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29250199/asco-update-on-lymphoma
#13
REVIEW
Michael A Fridrik
s concerning indolent and aggressive lymphoma and multiple myeloma with clinical relevance from the ASCO 2017 meeting are discussed.
2017: Memo
https://www.readbyqxmd.com/read/29246179/smoldering-mantle-cell-lymphoma
#14
REVIEW
Haige Ye, Aakash Desai, Dongfeng Zeng, Krystle Nomie, Jorge Romaguera, Makhdum Ahmed, Michael L Wang
BACKGROUND: Mantle cell lymphoma (MCL) is an aggressive disease, with poor prognosis and a limited survival. However, some patients with indolent MCL can survive beyond 7~10 years. These patients remain largely asymptomatic and can be in observation for a long time without any treatment. The process of "wait and watch" leaves these patients with the potential risk of evolution to classic, aggressive MCL. On the other hand, early treatment for these patients may not impact overall survival but rather affects the quality of life...
December 15, 2017: Journal of Experimental & Clinical Cancer Research: CR
https://www.readbyqxmd.com/read/29239080/hcv-positive-lymphoma-after-sustained-virological-response-with-direct-acting-antiviral-agents-the-game-is-not-over-after-hcv-eradication
#15
E Rodríguez de Santiago, K Velázquez Kennedy, M García González, F Gea Rodríguez, L Téllez Villajos, E Tavío Hernández, A Albillos Martínez
We read with interest the study published by Schiavinato A. et al. entitled: " Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents"[1]. There is extensive data supporting the association between hepatitis C virus (HCV) and B-cell non-Hodgkin lymphoma (B-cell NHL), especially with marginal zone and diffuse large B-cell NHL subtypes. Antiviral treatment with Interferon-based regimens has been shown to improve prognosis and can be curative in some cases of indolent lymphoma...
December 14, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29233743/a-phase-ii-trial-of-rituximab-combined-with-pegfilgrastim-in-patients-with-indolent-b-cell-non-hodgkin-lymphoma
#16
Pallawi Torka, Priyank Patel, Wei Tan, Gregory Wilding, Seema A Bhat, Myron S Czuczman, Kelvin P Lee, George Deeb, Vishala Neppalli, Cory Mavis, Paul Wallace, Francisco J Hernandez-Ilizaliturri
BACKGROUND: To explore the role of augmenting neutrophil function in B-cell lymphoma, we conducted a phase II study evaluating the safety and clinical efficacy of pegfilgrastim and rituximab in low-grade CD20+ B-cell non-Hodgkin lymphoma (B-NHL). PATIENTS AND METHODS: Twenty patients with indolent B-NHL were treated with rituximab (375 mg/m2) every other week for 4 doses, followed by every 2 months for 4 additional doses. Pegfilgrastim was administered subcutaneously 3 days before each dose of rituximab...
January 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29228725/distinct-clinical-characteristics-draw-a-new-prognostic-model-for-splenic-marginal-zone-lymphoma-in-hbv-high-prevalent-region
#17
Shuhua Yi, Yuting Yan, Wenjie Xiong, Rui Lv, Zhen Yu, Wei Liu, Enbin Liu, Heng Li, Huimin Liu, Zengjun Li, Gang An, Yan Xu, Kun Ru, Dehui Zou, Lugui Qiu
Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell neoplasm with hepatitis virus supposed to involve in the pathogenesis. The characteristics of SMZL derived from Caucasia population and high hepatitis C virus (HCV) infection region have been widely investigated, but few was reported in the Eastern population with HBV prevalent region. We analyzed the clinical characteristics, cytogenetic aberrations and prognostic factors in 160 SMZL patients from China. 25 patients (16%) were HBsAg-positive and 54 (34%) patients with resolved HBV infection...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29228090/epstein-barr-virus-positive-extranodal-marginal-zone-lymphoma-of-bronchial-associated-lymphoid-tissue-in-the-posttransplant-setting-an-immunodeficiency-related-posttransplant-lymphoproliferative-disorder
#18
Daniel P Cassidy, Francisco Vega, Jennifer R Chapman
Objectives: Posttransplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of hematolymphoid proliferations arising in the context of chronic immunosuppression. The common and indolent B-cell lymphomas, including extranodal marginal zone lymphomas (ENMZLs) of mucosa-associated lymphoid tissue (MALT), are excluded from the category of PTLD in the current World Health Organization classification. Methods: We report a case of Epstein-Barr virus (EBV)-positive bronchial-associated lymphoid tissue (BALT) lymphoma involving the lungs of a transplant patient...
December 7, 2017: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/29225983/breast-implant-associated-anaplastic-large-cell-lymphoma-a-case-report-and-review-of-the-literature
#19
Daniel E Ezekwudo, Tolulope Ifabiyi, Bolanle Gbadamosi, Kristle Haberichter, Zhou Yu, Mitual Amin, Kenneth Shaheen, Michael Stender, Ishmael Jaiyesimi
Breast implant-associated anaplastic large T-cell lymphoma has recently been recognized as an entity, with few reports describing the two common subtypes: in situ (indolent) and infiltrative. Recently, the infiltrative subtypes have been shown to be more aggressive requiring adjuvant chemotherapy. We report a rare case of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) in a 65-year-old Caucasian female following silicone breast implantation and multiple capsulectomies. We discuss the rare presentation of this disease, histopathologic features of the indolent and infiltrative subtypes of ALCL, and their clinical significance...
2017: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/29224288/-indolent-lymphoproliferative-disorder-and-lymphoma
#20
X S Fan, L He, J Y Chen, Y Fu, X J Zhou
No abstract text is available yet for this article.
December 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
keyword
keyword
99818
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"